Weekly Digest: Advances and Insights in Weight Management, Healthy Living, and Nutrition

This week revealed significant progress in medical treatments, public health trends, diet science, and healthcare policy affecting weight management and healthy living. Breakthrough medications combining powerful hormones have shown unprecedented weight loss results while new data reveal encouraging shifts in obesity prevalence. Nutritional studies reinforce the benefits of traditional diets, and evolving healthcare policies reflect challenges with medication access. Highlighted below are evidence-based findings from recent research and news.

1. Novo Nordisk's CagriSema: A First-of-Its-Kind Weight Loss Combination

In a groundbreaking development, Novo Nordisk submitted an FDA application for CagriSema, the first once-weekly injectable combining a GLP-1 receptor agonist (semaglutide) with a novel amylin analogue (cagrilintide) for chronic weight management. Clinical trial REDEFINE 1 showed adults without diabetes achieved an average 22.7% body weight loss at 68 weeks versus 2.3% in placebo. Additionally, 91.9% of participants lost at least 5% of their weight, and 54% of those with obesity reached non-obese BMI status. This dual hormone therapy exemplifies next-generation anti-obesity treatments.
Source: biospace.com

2. U.S. Adult Obesity Rate Shows First Decline Since 2022 Peak

According to Gallup polls and public health data, the adult obesity rate in the U.S. dropped from a high of 39.9% in 2022 to 37.0% in 2025. This translates to roughly 7.6 million fewer obese adults. The number of states with obesity rates above 35% decreased from 23 to 19. This decline aligns with increased adoption of GLP-1 injectable drugs, whose usage doubled from 5.8% in early 2024 to 12.4% in 2025. Women's usage outpaces men's (15.2% vs. 9.7%), indicating a growing role of pharmacotherapy alongside lifestyle changes.
Source: gallup.com

3. Eli Lilly's Oral Obesity Pill Orforglipron Maintains Weight Loss Post-Injection

Clinical trial findings for Eli Lilly's oral obesity drug orforglipron demonstrate that patients maintained weight loss achieved with injectable medications like Wegovy and Zepbound. Patients switching from Wegovy saw weight regain averaging only 0.9 kg over one year, while those switching from Zepbound gained an average of 5 kg, still maintaining significant overall reduction. This orally administered medication offers a convenient alternative to weekly injections and is currently under FDA review.
Source: statnews.com

4. Mediterranean Diet Significantly Reduces Inflammation Biomarkers

A comprehensive meta-analysis of 33 randomized controlled trials involving 3,476 participants reveals that adherence to the Mediterranean diet significantly lowers key inflammation markers such as high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and interleukin-17 (IL-17). The effects were most pronounced in individuals younger than 60 years and those with cardiovascular conditions during interventions shorter than 12 weeks. This anti-inflammatory effect underpins the Mediterranean diet's documented benefits for cardiovascular and metabolic health.
Source: pubmed.ncbi.nlm.nih.gov

5. Challenges in GLP-1 Weight Loss Medication Coverage and Access

Despite rising usage of GLP-1 medications such as Wegovy and Zepbound, cost barriers and insurance coverage gaps remain significant. HCA Healthcare announced it will discontinue coverage for these drugs in 2026, citing a 90% surge in utilization which markedly increased costs. Employees are instead directed to manufacturer discount programs with cash prices ranging from $149 to $450 monthly. Studies indicate that 40% of GLP-1 prescriptions go unfilled, with substantial disparities: Black patients have a 55.3% fill rate, Hispanic patients 58.4%, and white patients 60.9%. Average copays remain high even with insurance.
Source: harvard.edu

This week's updates collectively highlight the ongoing evolution in weight management through innovative drug therapies, promising dietary patterns, and population health changes. They also emphasize the continuing challenges in equitable access to effective treatments. These data-driven insights underscore the complex interplay of biology, behavior, and policy shaping healthy living today.

Sources

• https://www.biospace.com/press-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp-1-and-amylin-analogues-for-weight-management
• https://news.gallup.com/poll/696599/obesity-rate-declining.aspx
• https://www.statnews.com/2025/12/18/eli-lilly-obesity-pill-orforglipron-maintain-weight-loss/
• https://pubmed.ncbi.nlm.nih.gov/41211687/
• https://news.harvard.edu/gazette/story/2025/12/is-cost-curbing-use-of-weight-loss-drugs/